Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

ClinicalTrials.gov ID: NCT04948099

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04948099. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 1:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A first-in-human study to evaluate the safety and tolerability of escalating, single and multiple ascending doses of VIB1116 in adult participants with rheumatic diseases.

Study identification

NCT ID
NCT04948099
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Amgen
Industry
Enrollment
73 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 6, 2021 (Actual)
Primary completion
Jul 3, 2023 (Actual)
Completion
Jul 3, 2023 (Actual)
Last update posted
Dec 13, 2024

2021 – 2023

United States locations

U.S. sites
8
U.S. states
5
U.S. cities
8
Facility City State ZIP Site status
Pinnacle Research Group Anniston Alabama 36207 —
Clinical Research of W FL Clearwater Florida 33765-2616 —
Jacksonville Clinical Research Jacksonville Florida 32216-4362 —
Accurate Clinical Research Lake Charles Louisiana 70605 —
Altoona Clinical Research Duncansville Pennsylvania 16635-8445 —
Rheumatology Associates Dallas Texas 75231 —
SW Rheumatology Center Mesquite Texas 75150-6919 —
Clinical Trials of Texas, Inc. San Antonio Texas 78229-3539 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04948099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 13, 2024 · Synced Nov 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.